• 1
    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.
  • 2
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-1947.
  • 3
    Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of 6 genes. N Engl J Med. 2004; 350: 1828-1837.
  • 4
    Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571-578.
  • 5
    Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011; 29: 1844-1854.
  • 6
    Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012; 30: 184-190.
  • 7
    Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of International Harmonization Project interpretation. J Nucl Med. 2011; 52: 386-392.
  • 8
    Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012; 119: 2066-2073.
  • 9
    Kim T, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B-cell lymphoma. Cancer. 2013; 119: 1195-1202.
  • 10
    Ramsdale E, van Besien K, Smith SM. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011; 38: 225-235.
  • 11
    Schoder H, Noy A, Gonen M, et al. Intensity of 18-fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 4643-4651.
  • 12
    Gaudio F, Giordano A, Perrone T, et al. High Ki-67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011; 126: 44-51.
  • 13
    Park S, Moon SH, Park LC, et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012; 87: 937-940.
  • 14
    Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012; 91: 697-703.
  • 15
    Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011; 118: 37-43.
  • 16
    Pfreundschuh M, Kuhnt E, Trumper L, et al; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011; 12: 1013-1022.